(Q34992631)

5 August 2017

1 reference

title

Initial therapy of HIV infection (English)

1 reference

5 August 2017

Joel E Gallant

1

1 reference

5 August 2017

publication date

1 December 2002

1 reference

Journal of Clinical Virology

5 August 2017

published in

1 reference

5 August 2017

volume

25

1 reference

5 August 2017

issue

3

1 reference

5 August 2017

page(s)

317-333

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

5 August 2017

1 reference

7 January 2021

In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Nelfinavir: an update on its use in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

HIV-1 drug resistance in newly infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Factors affecting adherence to antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus G

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Strategies for long-term success in the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Anti-HIV effect of saquinavir combined with ritonavir is limited by previous long-term therapy with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Safety and activity of saquinavir in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Reduced antiretroviral drug susceptibility among patients with primary HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Hepatotoxicity associated with ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

Transmission of antiretroviral-drug-resistant HIV-1 variants

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900024-0

7 January 2021

10.1016/S1386-6532(02)00024-0

Identifiers

DOI

1 reference

5 August 2017

1 reference